Innovation Medical(SZ:002173) Sou Hu Cai Jing·2025-07-22 01:57Core Viewpoint - The AI Fund Dongfang Innovation Medical Stock A (018045) reported a profit of 1.0433 million yuan for Q2 2025, with a net value growth rate of 6.3% during the period, and a fund size of 16.5886 million yuan as of the end of Q2 2025 [3][16]. Fund Performance - The fund's unit net value as of July 21 was 1.095 yuan, with a near-term performance showing a 21.77% growth rate over the last three months, ranking 30 out of 54 comparable funds [4]. - Over the past six months, the fund achieved a growth rate of 33.61%, ranking 27 out of 54, and a one-year growth rate of 40.14%, ranking 22 out of 53 [4]. Investment Strategy - The fund employs a top-down industry segmentation approach combined with a bottom-up stock selection strategy, focusing on innovative industry chains, pharmacies, consumer healthcare, and equipment upgrades while avoiding sectors in decline [4]. - The fund manager maintains an optimistic outlook on the medical industry, driven by aging populations and continuous demand for healthcare, aiming for long-term returns by selecting leading companies with strong fundamentals [4]. Fund Metrics - The fund's Sharpe ratio since inception is 0.2608, indicating a moderate risk-adjusted return [9]. - The maximum drawdown since inception is 28.85%, with the highest quarterly drawdown recorded at 23.3% in Q1 2024 [12]. Fund Holdings - As of June 27, the fund's average stock position was 73.6%, compared to the industry average of 88.2%. The fund reached a peak stock position of 91.98% at the end of H1 2025 [15]. - The top ten holdings of the fund include companies such as Yuekang Pharmaceutical, Maiwei Biotechnology, and Heng Rui Medicine [18].